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The capsid of the foot and mouth disease (FMD) virus
carries the epitopes that are critical for inducing the
immune response. In an attempt to enhance the specific
immune response, plasmid DNA was constructed to
express VP1/interleukin-1α (IL-1α) and precursor capsid
(P1) in combination with 2A (P1-2A)/IL-1α under the
control of the human cytomegalovirus (HCMV) immediate-
early promoter and intron. After DNA transfection into
MA104 (monkey kidney) cells, Western blotting and an
immunofluorescence assay were used to confirm the
expression of VP1 or P1-2A and IL-1α. Mice were
inoculated with the encoding plasmids via the intradermal
route, and the IgG1 and IgG2a levels were used to
determine the immune responses. These results show that
although the immunized groups did not carry a high level
of neutralizing antibodies, the plasmids encoding the VP1/
IL-1α, and P1-2A /IL-1α fused genes were effective in
inducing an enhanced immune response.
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Introduction
Foot and mouth disease (FMD) is one of the most
devastating diseases in cattle, swine, sheep, goats, and many
wild cloven-hoofed animal species [2]. The causative agent
of the disease belongs to the Aphthoviruses genus of the
Picornaviridae Family.
In recent years, DNA vaccination has become one of the
most promising routes for a recombinant vaccine [8,12],
allowing a safe and efficient alternative to conventional
vaccination. DNA vaccine technology facilitates the use of
cytokines as modulators in vaccination to manipulate the
immune responses. In particular, IL-1 production by
mononuclear phagocytes can be triggered by macrophage-
derived cytokines such as tumor necrosis factor (TNF) or
Interleukin-1 (IL-1), as well as by contact with CD4
+ T cells.
IL-1α is a major immunoregulatory and proinflammatory
cytokine that also affects the proliferation and function of
fibroblast [3,6]. Recently, we observed that DNA vaccination
using both IL-1α and the porcine reproductive and
respiratory syndrome virus (PRRSV) ORF5 gene induced a
stronger immune response compared with IL-1β administered
through the intradermal route in the tail (data not shown).
The DNA vaccines are generally used at high concentrations
in mouse immunizations, approximately 100-200 µg per
animal, as well as in a highly purified form to remove endotoxins
derived from E. coli. Therefore, a low administration dose is
important for clinical applications.
The aim of the study was to examine the efficiency of a
DNA immunization system using plasmids at low doses in
mice, and to enhance the immunogenicity against FMD by
constructing plasmids containing the swine IL-1α gene in
addition to the viral capsid (P1) gene including 2A or VP1
containing the major epitopes of the virus.
Materials and Methods
Construction of plasmids
The vector pSLIA, which was kindly supplied by VIDO
(Vaccine and Infectious Disease Organization, Canada), is a
stable mammalian expression vector that contains the CMV
promoter for expression in mammalian cells. Swine IL-1α,
as a molecular adjuvant, was cloned from the whole blood
of pigs. The VP1 and P1-2A (P1 and 2A) cDNA from the O/
SKR/2002 strain (AY312588) were amplified by a polymerase
chain reaction (PCR). The sense and anti-sense primers used
for VP1 were 5'-AACTGCAGATGACCACCTCCACAGG
TGAGT-3' and 5’-CGGGATCCCAACAGCTGTTTCACA
GGCGCC-3', respectively. The sense and anti-sense primers
used for P1-2A (truncated form of 5' region) 5'-GCTCTAG
AATGAACACTGGAAGCATTATCA-3' and 5'-CGGGAT
CCCCCAGGGTTGGGCTCGACGTCT-3', respectively. The
amplified PCR products corresponding to VP1 or P12A
*Corresponding author
Tel: +82-31-467-1719; Fax: +82-31-449-5882
E-mail: parkjh@nvrqs.go.kr258 Jong Hyeon Park et al.
were purified from a gel using Gene Clean Turbo kit (Q-
BIO Gene, USA) and cloned into the PstI and BamHI, or
XbaI and BamHI sites of pSLIA. The resulting plasmids
were named pS-VP1, pSIL1A-VP1 and pSIL1A-P12A (Fig. 1).
Identification of expressed viral protein
MA104 cells, a monkey kidney cell line, were transfected
using Lipofectamine plus (Gibco, USA) according to the
manufacturer's instructions. The cells were incubated with
bovine FMDV antiserum. After incubation, the cells were
washed with PBS and incubated with the fluorescein
isothiocyanate (FITC)-conjugated goat anti-bovine antibody
(Cappel, USA). The cells were kept in PBS and observed by
fluorescence microscopy.
For Western blotting, the MA104 cells were cultured on a
tissue culture dish (100mm) and transfected with Lipofectamine
plus, as described above. After 48 h of transfection, the cells
were harvested using centrifugation, and disrupted with a
lysis buffer and sonication. After electrophoresis in SDS-
PAGE gel, the gels were transferred onto a nitrocellulose
membrane, and the membrane was reacted with either the
bovine FMDV antibody (NVRQS, Korea) or rabbit anti-
swine IL-1α antibody (Biosource, USA). The first antibody
was detected by horseradish peroxidase (HRPO)-anti-
immunoglobulin conjugate and visualized by diamino-
benzidine staining of the nitrocellulose membrane.
Immunizations to mice
A total of twenty specific pathogen free (SPF) C57BL/6
mice (4-8 week olds, male), which were grown according to
the animal management guideline of the National Veterinary
Research and Quarantine Service (NVRQS) in Korea, were
divided into 4 groups (5 mice/group) for the DNA immunization
clinical trial. One week prior to the experiment, the mice
were isolated, and kept under controlled conditions for the
duration of the study. The control group mice were
inoculated with pSLIA and each of the three experimental
groups were administered with pS-VP1, pSIL1A-VP1 or
pSIL1A-P12A, respectively. The mice were immunized
three times with a low dose of the plasmids (10 µg) by a tail
injection. The antibody response was examined from blood
samples collected from the four groups of mice over a 7 day
period before inoculation, and at 2 or 3 week intervals after
inoculation.
Measurement of Anti-VP1 or anti-P12A antibody level
The immune responses after DNA vaccination were
determined by indirect ELISA as described by Abu Elzein
and Crowther [1]. Ninety-six well plates (Nunc, Denmark)
were coated with inactive purified FMDV serotype O antigen
(10
5 tissue culture infectious dose (TCID) 50/ml) overnight
and incubated with the serum samples [1 : 50 diluted in
0.1 M PBS containing 0.5% Tween 20 and 0.5% gelatin] for
1 h at 37
oC. For each mouse IgG subtyping, biotinylated
goat IgG specific to either mouse IgG or IgG1/IgG2a
(Zymed Laboratory, USA) was reacted for 30 min at 37
oC.
After the reaction with the HRP-streptavidin conjugate for
30 min at 37
oC, the color reaction was developed with 100
µl/well of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) for 30 min at room temperature, and the absorbance
was examined at a wavelength of 405 nm. The results are
expressed as the reciprocal of the highest serum dilution
resulting in a reading of two standard deviations above the
value of the control sera. The serum neutralizing antibody
test and liquid-phase blocking (LPB) ELISA was carried out
according to the OIE Terrestrial Manual [4].
Fig. 1. Schematic diagram of plasmid constructs expressing various FMDV proteins in the DNA-based mammalian expression vector s
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Results
VP1 and P12A proteins expressed in MA104 cells
The expression of the recombinant proteins in MA104
cells were analyzed using an immunofluorescence assay and
Western blot analysis after 48 h of transfection. No bright
staining was detected when the test cells were transfected
with the pSLIA control vector, whereas high levels of bright
fluorescent staining due to a specific reaction of the bovine
antiserum and rabbit antiserum to the cytosol proteins were
detected in the pS-VP1, pSIL1A-VP1 or pSIL1A-P12A
transfected cells. The expression of the P12A protein appeared
to be higher than that of the VP1 protein (Fig. 2).
The proteins secreted after 48 h of transfection were
analyzed by SDS-PAGE. The separated proteins were
transferred onto a nitrocellulose membrane. The proteins in
the cell lysates of the transfected MA104 cells were
immunodetected by Western blot analysis, using rabbit anti-
swine IL-1α and bovine antiserum. Fig. 3 shows that the cell
lysates of the pS-VP1, pSIL1A-VP1 and pSIL1A-P12A
transfected MA104 cells expressed a detectable level of the
recombinant proteins. The VP1, VP1-IL1α and P12A-IL1α
fusion protein bands were detected with a molecular weight
corresponding to 25 kDa (lane 2), 65 kDa (lane 3) and 120
kDa (lane 4), respectively.
Fig. 2. Detection of recombinant proteins in pS-VP1, pSIL1A-
VP1 and pSIL1A-P12A transfected cells by immunofluorescen t
assay with bovine anti-FMDV serum. A. pSLIA transfecte d
MA104 cells as a control, B. pS-VP1 transfected MA104 cells C.
pSIL1A-VP1 transfected MA104 cells, D. pSIL1A-P12A
transfected MA104 cells.
Fig. 3. Expression of recombinant proteins in transfected cells as detected by Western blot analysis with swine IL-1 α antibody (A) or
bovine FMDV- antiserum (B). Lysates of MA104 cells transfected with recombinant plasmids were analysis by electrophoretically
transferred to nitrocellulose membrane for Western blot analysis. M; Protein molecular weight marker (Invitrogen), lane 1; pSLI A
transfected MA104 cells as a control, lane 2; pS-VP1 transfected MA104 cells, lane 3; pSIL1A-VP1 transfected MA104 cells, lane  4;
pSIL1A-P12A transfected MA104 cells.260 Jong Hyeon Park et al.
Immunogenicity in mice
The mice (C57BL/6) were immunized through the tail
with 10 µg of either pSLIA (control group), pS-VP1, pSIL1A-
VP1 and pSIL1A-P12A. ELISA was used to determine the
level of the humoral antibody, and the anti-VP1 antibodies
one week after the third immunization. The group immunized
with the recombinant plasmids encoding IL-1α showed
higher titers than the group immunized without IL-1α (Fig.
4). The mice immunized with pSIL1A-P12A had a higher
titer than the mice immunized with pSIL1A-VP1 (Fig. 4A).
Fig. 4B shows a weak reaction in the sera of all four groups
one week after the first immunization. In the pSIL1A-VP1
and pSIL1A-P12A groups, an increase in the immune
response was detected in the sera one week after the second
immunization. However, no increase in the immune response
was detected in the pSLIA and pS-VP1 groups.
The changes in the immune response were detected by
IgG subclass analysis in the sera at one week after the third
immunization (Table 1). Immunizing the mice with pSIL1A-
VP1 and pSIL1A-P12A produced a specific IgG1 and IgG2a
response and showed an increased response by a ratio of
IgG1/IgG2a (Fig. 5).
Discussion
These results show that recombinant plasmids were
constructed with VP1, which contained the critical epitopes
for inducing an immune response to the FMDV [13] or the
capsid (P1) gene including 2A of the FMDV, which is a
mixture of genes encoding structural and non-structural
proteins. It was reported that the viral structural proteins
induce a humoral response, whereas the non-structural
proteins appear to be more effective in inducing the cellular
immune system [7]. Some recombinant plasmids were also
constructed to encode IL-1α in order to enhance the immune
response.
Fig. 4. Immune responses in the mice immunized with FMDV plasmids. (A) The ELISA was carried out with the sera from C57BL/6
mice (five per group). The test was determined at 1 week after the third immunization. The mice immunized with recombinant plas mids
encoding IL-1α showed high titers. The optical densitiy was measured at 405 nm. (B) C57BL/6 mice (five per group) were immunize d
three times with 10 µl of plasmids by tail injection. ELISA was carried out with each serum from five mice. The test sera from the
vaccinated animals were diluted 1 : 300 and optical density read at 405 nm. Similarly increased immune response in the pSIL1A-VP1
and pSIL1A-P12A group were detected in the sera at one week after the 2nd immunization.
Table 1. Properties of immune responses in mice immunized with various FMDV plasmids
Immunized groups Ratio of IgG1:IgG2a SN*
Mean titers for FMDV antibody
LPB** SPC
† Indirect ELISA
‡
pSLIA
§-
§ <4 <50 <50 <10
pS-VP1 - <4 <50 <50 28 ± 7.3
pSIL1A-VP1 3.5:1 <4 <50 <50 1,120 ± 587.8.
pSIL1A-P12A 3.6:1 4 <50 <50 2,560
*Pooled sera of five mice was tested for serum neutralizing (SN) activity.
**
 Percent inhibition (%) by
 liquid-phase blocking (LPB) ELISA for O type (Pirbright Institute, UK).
†Percent inhibition (%) by solid-phase competitive (SPC) ELISA for O type structural protein detection (Cedi-Diagnostics B.V., N etherland).
‡ Reciprocal titer of highest serum dilution by
 indirect ELISA as described in material and methods (NVRQS, Korea).
§ Not detected because the level is too low.Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes 261
The results showed that the recombinant plasmids, the
expression vector encoding VP1 or capsid (P1) gene including
2A, could be transfected to MA104 cells, which then
expressed VP1 or P12A. The molecular weight of the VP1
protein and the VP1 fusion protein containing IL-1α were
found at the predicted molecular weight. The P12A fusion
protein band was observed by 3C protease with natural
processing to be a large protein without the proteolytic
cleavage form. These results suggest that the pSILIA-VP1
and pSIL1A-P12A expression plasmids can transfect cells,
resulting in the expression of VP1 and P12A proteins in
linearized forms. In this study, these plasmids could be
expressed in mammalian cells by transfection in vitro.
The recombinant proteins and synthetic peptides are often
weak immunogens that require the addition of adjuvants to
potentiate the immune reactivity [9]. There have been many
studies on the use of cytokines as adjuvants in vaccination.
Cytokines inducing IL-1 and IL-2 are frequently used in
combination with viral antigens to enhance their immuno-
genicity [10]. IL-1 has been shown to be an effective
adjuvant in several model systems, enhancing the protection
induced by a viral and bacterial vaccine as well as
stimulating the immunity in clinical trials, even though side
effects such as fever have been reported. IL-1 molecules
have diverse biological activity that are important for
immune reactivity, such as inducing the cells to synthesize
more of the other cytokines and activating T cell, inflammation
and auto-immunity [5]. Among the various animal species,
the mature IL-1α sequences are conserved in a range of
approximately 70% [11].
This study demonstrated that the administration of the
swine IL-1α gene significantly enhanced the immune
response in mice, and the recombinant plasmids encoding
IL-1α in combination could be an effective immunogen.
Indirect ELISA was used to measure the antibody level in
the mice immunized with pS-VP1, pSIL1A-VP1 and pSIL1A-
P12A. The pSIL1A-VP1 and pSIL1A-P12A showed a
similar increase in the immune response in the sera at 1
week after the 2nd immunization compared with the pSLIA
group, while the pS-VP1 group showed a low immune
response.
In FMD, it is important that the humoral response elicits
rapid protection on account of the rapid progression of the
disease. There is also the issue of having to deliver the
vaccine in low doses because of the difficulty associated
with the production of sufficient vaccine. For these reasons,
an attempt was made to achieve enhanced immunity through
intradermal route through the tail skin, which contains
immune stimulating cells such as macrophages or dendritic
cells.
The formation of IgG2a is typical for the Th1 response,
while IgG1 is typical for Th2 response [10]. In this study, the
immunization of mice with pS-VP1, pSIL1A-VP1 and
pSIL1A-P12A increased the IgG1/IgG2a ratio in low
dilution sera. It is possible that even though no attempt was
made to detect the cytokines associated with the cellular
immunity, these patterns are typical of the Th2 response.
Th2 type cells have been reported to be efficient in helping
induce an antibody response to protein antigens [7].
The neutralizing responses in the vaccinated group were
either very low or could be not detected by the neutralizing
test or LPB ELISA. This might be due to the poor
conformational epitope to elicit protection against a viral
challenge. In order to overcome this problem, a better
strategy might be to add 3C protease to the P1 region or
express multiple cistronic VP0/VP3/VP1 to mimic the
immunogenicity of the conformational epitopes in the
authentic structure.
DNA immunization provides a safe and efficient alternative
to conventional vaccination. The plasmid DNA vaccines
encoding the foot and mouth disease virus VP1 epitopes
have the ability to elicit both FMDV-specific T cell
proliferation and neutralizing antibody against FMD in
swine [13]. Moreover, despite the difficulties associated
with needle vaccination, the recombinant plasmid has other
advantages, such as increased safety, reproducibility, and
ease of production.
In conclusion, the VP1, P12A and IL-1α fusion genes
might be useful as strong immunogens. However, research
concerning protection conferred by the capsid and IL-1 co-
expressed plasmids on other target animals such as swine
and cattle is needed. Studies aimed at replacing a DNA
vaccination strategy with an adenovirus and retrovirus gene
delivery system to achieve more efficient vaccination are
currently underway.
Fig. 5. Levels of IgG subclass in the mice immunized with
FMDV plasmids. The T cell response was tested by IgG subclass
analysis in the sera from C57BL/6 mice (five per group) at one
week after 3rd immunization. The test sera from the vaccinate d
animals were diluted 1 : 50 and optical density read at 405 nm.
The mice immunized with pSIL1A-VP1 and pSIL1A-P12A
elicited specific IgG1 and IgG2a response and increased the ratio
of IgG1/IgG2a.262 Jong Hyeon Park et al.
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